In this study, we investigated the molecular mechanisms underlying the oncogenic activity of activated FGFR3 in bladder tumors, with a view to identifying new drug targets to improve treatment efficacy and/or limit resistance. Here, FGFR3 is linked to urinary bladder neoplasm.